Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation

Rick D. Fannin, Mark Russo, Thomas M. O'Connell, Kevin Gerrish, Jason H. Winnike, Jeffrey Macdonald, Jack Newton, Shahid Malik, Stella O. Sieber, Joel Parker, Ruchir Shah, Tong Zhou, Paul B. Watkins, Richard S. Paules – 23 December 2009 – The diagnosis and management of drug‐induced liver injury (DILI) is hindered by the limited utility of traditional clinical chemistries. It has recently been shown that hepatotoxicants can produce compound‐specific changes in the peripheral blood (PB) transcriptome in rodents, suggesting that the blood transcriptome might provide new biomarkers of DILI.

Major histocompatibility complex class I–related chains A and B (MIC A/B): A novel role in nonalcoholic steatohepatitis

Alisan Kahraman, Martin Schlattjan, Peri Kocabayoglu, Sule Yildiz‐Meziletoglu, Matthias Schlensak, Christian D. Fingas, Inga Wedemeyer, Guido Marquitan, Robert K. Gieseler, Hideo A. Baba, Guido Gerken, Ali Canbay – 23 December 2009 – Stress‐induced soluble major histocompatibility complex class I–related chains A/B (MIC A/B) are increased in chronic liver diseases and hepatocellular malignancy. We investigated the impact of these molecules on liver injury, apoptosis, and fibrosis in nonalcoholic steatohepatitis (NASH).

Impaired expression and function of toll‐like receptor 7 in hepatitis C virus infection in human hepatoma cells

Serena Chang, Karen Kodys, Gyongyi Szabo – 23 December 2009 – Hepatitis C virus (HCV) interferes with interferon (IFN)‐mediated innate immune defenses. Toll‐like receptor (TLR) 7 agonists robustly inhibit HCV infection. We hypothesize that HCV infection may interfere with the expression and/or function of TLR7, a sensor of single‐stranded RNA. We identified reduced TLR7 RNA and protein levels in hepatoma cells expressing HCV (full‐length, BB7‐subgenomic, and JFH‐1 clone) compared with control HCV‐naïve cells.

A peer‐based intervention to educate liver transplant candidates about living donor liver transplantation

Samantha DeLair, Thomas Hugh Feeley, Hyunjung Kim, Juan del Rio Martin, Leona Kim‐Schluger, Dianne LaPointe Rudow, Mark Orloff, Patricia A. Sheiner, Lewis Teperman – 23 December 2009 – The number of liver donors has not measurably increased since 2004 and has begun to decrease. Although many waitlisted patients may be suitable candidates to receive a living donor graft, they are often reticent to discuss living donation with close friends and family, partly because of a lack of knowledge about donor health and quality of life outcomes after donation.

Acute portal vein thrombosis unrelated to cirrhosis: A prospective multicenter follow‐up study

Aurelie Plessier, Sarwa Darwish‐Murad, Manuel Hernandez‐Guerra, Yann Consigny, Federica Fabris, Jonel Trebicka, Jorg Heller, Isabelle Morard, Luc Lasser, Philippe Langlet, Marie‐Hélène Denninger, Dominique Vidaud, Bertrand Condat, Antoine Hadengue, Massimo Primignani, Juan‐Carlos Garcia‐Pagan, Harry L. A. Janssen, Dominique Valla, European Network for Vascular Disorders of the Liver (EN‐Vie) – 23 December 2009 – Current recommendations for early anticoagulation in acute portal vein thrombosis unrelated to cirrhosis or malignancy are based on limited evidence.

Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype‐specific immunodominant CD8+ T‐cell epitope

Christoph Neumann‐Haefelin, Jörg Timm, Julia Schmidt, Nadine Kersting, Karen Fitzmaurice, Cesar Oniangue‐Ndza, Michael N. Kemper, Isla Humphreys, Susan McKiernan, Dermot Kelleher, Volker Lohmann, Paul Bowness, Daniela Huzly, Hugo R. Rosen, Arthur Y. Kim, Georg M. Lauer, Todd M. Allen, Eleanor Barnes, Michael Roggendorf, Hubert E. Blum, Robert Thimme – 23 December 2009 – Human leukocyte antigen B27 (HLA‐B27) is associated with protection in human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection.

Subscribe to